SlideShare a Scribd company logo
1 of 13
Managing both nasal and ocular symptoms in patients with moderate to severe seasonal allergic rhinitis (SAR) “When we think about allergic rhinitis, we forget that the eyes come along.” http://kardzmed.com OBJECTIVE:
that about 75% of the most severe SAR patients complain of itchy eyes and about two thirds of them complain of watery eyes there's been a lot of interest in looking at combinations of nasal antihistamines and nasal corticosteroids, with previous studies showing that the combination is more effective statistically than the single entities http://kardzmed.com Basis of Research
Paul Ratner, MD, allergist/immunologist and founder and director of Sylvana Research, of San Antonio, Texas, a research facility for investigational medications. http://kardzmed.com Lead Reasearcher
the ocular effects from treatment with this combination. http://kardzmed.com Aim of study“Treat the Eyes and the Nose”
His investigational team enrolled 610 patients with ocular symptoms from SAR during the 2007/08 Texas Mountain Cedar season.  The patients were randomized to 1 of 4 groups receiving 1 spray per nostril twice daily: azelastine alone, fluticasone alone, azelastine plus fluticasone, and placebo. http://kardzmed.com Procedure
The primary end point was efficacy, defined as a change from baseline in the total nasal symptom score (TNSS) for nasal congestion, sneezing, itchy nose, and runny nose. The secondary end point was the effect of azelastine plus fluticasone on the total ocular symptom score (TOSS) for itchy eyes, watery eyes, and redness http://kardzmed.com Set objectives to investigate
Results were presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2009 Annual Scientific Meeting in a podium session http://kardzmed.com Results
Nasal and Ocular Symptoms Improved  improvements on TNSS were statistically significant for the patients treated with the combination spray compared with single drug http://kardzmed.com 1. TNSS
There was also a statistically significant improvement in TOSS for those treated with the combination spray http://kardzmed.com 2. TOSS
The only adverse events reported by more than 2% of those treated with the combination spray were bitter taste (7.2%),  epistaxis(3.9%),  and headache (2.6%). http://kardzmed.com adverse effects
The first is that the combination therapy with nasal antihistamines and nasal steroids is definitely panning out to be more effective than treatment with the individual components Second, in addition to treating the nasal symptoms that you would expect, you're also getting the added benefit of having relief of the ocular symptoms." http://kardzmed.com Conclusion
allergists are now using both drugs in combination in 30% to 40% of their patients. So what this study reinforces is that polypharmacy, using an antihistamine blocker as well as a nasal steroid, may be a more effective modality in treating this ocular complaint and the nasal symptoms http://kardzmed.com
This study was funded by Meda pharmaceuticals November 13, 2009 (San Diego, California) Presented in ENT class (Ml410)  by Dr. Karl  http://kardzmed.com http://kardzmed.com THE END

More Related Content

Viewers also liked

Midterm presentation 2.27.2010 small
Midterm presentation 2.27.2010 smallMidterm presentation 2.27.2010 small
Midterm presentation 2.27.2010 smallguestc8839dc3
 
Cauchuyendang xem
 Cauchuyendang xem Cauchuyendang xem
Cauchuyendang xemDamPhan
 
Bideoaetahezkuntza
BideoaetahezkuntzaBideoaetahezkuntza
Bideoaetahezkuntzapatricia
 
Using smart phones as part
Using smart phones as partUsing smart phones as part
Using smart phones as partcindy spaedy
 
How do I get the most value out of my technology investments?
How do I get the most value out of my technology investments?How do I get the most value out of my technology investments?
How do I get the most value out of my technology investments?Anupam Kundu
 
JSR life science product of Magnetic beads
JSR life science product of Magnetic beadsJSR life science product of Magnetic beads
JSR life science product of Magnetic beadsmasaaki24m
 
Il progetto CSP White FI
Il progetto CSP White FI Il progetto CSP White FI
Il progetto CSP White FI CSP Scarl
 
A rnau cairo
A rnau cairoA rnau cairo
A rnau cairoarnau19
 
D:\Ring O 2nd Grade
D:\Ring O 2nd GradeD:\Ring O 2nd Grade
D:\Ring O 2nd Gradeguest5ac3f31
 
Todos los trabajos
Todos los trabajos Todos los trabajos
Todos los trabajos Juliiita
 
2012 Iowa Caucuses in Pictures Channel 4 News Tawanda Kanhema
2012 Iowa Caucuses in Pictures Channel 4 News Tawanda Kanhema2012 Iowa Caucuses in Pictures Channel 4 News Tawanda Kanhema
2012 Iowa Caucuses in Pictures Channel 4 News Tawanda KanhemaTawanda Kanhema
 
Backupify CloudInno Presentation by Rob May
Backupify CloudInno Presentation by Rob MayBackupify CloudInno Presentation by Rob May
Backupify CloudInno Presentation by Rob MayDatto
 
alternatives to hysterectomy
alternatives to hysterectomyalternatives to hysterectomy
alternatives to hysterectomyKarl Daniel, M.D.
 
Storie dal futuro: persone e cose sempre connesse
Storie dal futuro: persone e cose sempre connesseStorie dal futuro: persone e cose sempre connesse
Storie dal futuro: persone e cose sempre connesseCSP Scarl
 
Expeditie mont blanc
Expeditie mont blancExpeditie mont blanc
Expeditie mont blancElisabeth
 

Viewers also liked (18)

Report on torture
Report on tortureReport on torture
Report on torture
 
Midterm presentation 2.27.2010 small
Midterm presentation 2.27.2010 smallMidterm presentation 2.27.2010 small
Midterm presentation 2.27.2010 small
 
Cauchuyendang xem
 Cauchuyendang xem Cauchuyendang xem
Cauchuyendang xem
 
Brain storming-rules
Brain storming-rulesBrain storming-rules
Brain storming-rules
 
Bideoaetahezkuntza
BideoaetahezkuntzaBideoaetahezkuntza
Bideoaetahezkuntza
 
Using smart phones as part
Using smart phones as partUsing smart phones as part
Using smart phones as part
 
How do I get the most value out of my technology investments?
How do I get the most value out of my technology investments?How do I get the most value out of my technology investments?
How do I get the most value out of my technology investments?
 
JSR life science product of Magnetic beads
JSR life science product of Magnetic beadsJSR life science product of Magnetic beads
JSR life science product of Magnetic beads
 
Il progetto CSP White FI
Il progetto CSP White FI Il progetto CSP White FI
Il progetto CSP White FI
 
A rnau cairo
A rnau cairoA rnau cairo
A rnau cairo
 
D:\Ring O 2nd Grade
D:\Ring O 2nd GradeD:\Ring O 2nd Grade
D:\Ring O 2nd Grade
 
Todos los trabajos
Todos los trabajos Todos los trabajos
Todos los trabajos
 
2012 Iowa Caucuses in Pictures Channel 4 News Tawanda Kanhema
2012 Iowa Caucuses in Pictures Channel 4 News Tawanda Kanhema2012 Iowa Caucuses in Pictures Channel 4 News Tawanda Kanhema
2012 Iowa Caucuses in Pictures Channel 4 News Tawanda Kanhema
 
Backupify CloudInno Presentation by Rob May
Backupify CloudInno Presentation by Rob MayBackupify CloudInno Presentation by Rob May
Backupify CloudInno Presentation by Rob May
 
alternatives to hysterectomy
alternatives to hysterectomyalternatives to hysterectomy
alternatives to hysterectomy
 
Storie dal futuro: persone e cose sempre connesse
Storie dal futuro: persone e cose sempre connesseStorie dal futuro: persone e cose sempre connesse
Storie dal futuro: persone e cose sempre connesse
 
Claude monet
Claude monetClaude monet
Claude monet
 
Expeditie mont blanc
Expeditie mont blancExpeditie mont blanc
Expeditie mont blanc
 

More from Karl Daniel, M.D. (20)

menstrual cycle
menstrual cyclemenstrual cycle
menstrual cycle
 
vulvo vaginal infection
vulvo vaginal infectionvulvo vaginal infection
vulvo vaginal infection
 
vesicular molle 2
vesicular molle 2vesicular molle 2
vesicular molle 2
 
vesicular molle 1
vesicular molle 1vesicular molle 1
vesicular molle 1
 
Sexually Transmitted Infections
Sexually Transmitted InfectionsSexually Transmitted Infections
Sexually Transmitted Infections
 
Screening for Female Genital Tract Malignancy
Screening for Female Genital Tract MalignancyScreening for Female Genital Tract Malignancy
Screening for Female Genital Tract Malignancy
 
vaginal prolapse
vaginal prolapsevaginal prolapse
vaginal prolapse
 
prevention Cervical cancer
prevention Cervical cancerprevention Cervical cancer
prevention Cervical cancer
 
ovarian tumor
ovarian tumorovarian tumor
ovarian tumor
 
Contemporary Use of the Pessary
Contemporary Use of the PessaryContemporary Use of the Pessary
Contemporary Use of the Pessary
 
management of cancer of cervix
management of cancer of cervixmanagement of cancer of cervix
management of cancer of cervix
 
leiomyomas
leiomyomasleiomyomas
leiomyomas
 
fibroids
fibroidsfibroids
fibroids
 
endometriosis
endometriosisendometriosis
endometriosis
 
DnC
DnCDnC
DnC
 
carcinoma vulva
carcinoma vulvacarcinoma vulva
carcinoma vulva
 
amenorrhea
amenorrheaamenorrhea
amenorrhea
 
adenomyosis
adenomyosisadenomyosis
adenomyosis
 
Evidence Based Diagnosis
Evidence Based DiagnosisEvidence Based Diagnosis
Evidence Based Diagnosis
 
HORMONE REPLACEMENT THERAPY 2
HORMONE REPLACEMENT THERAPY 2HORMONE REPLACEMENT THERAPY 2
HORMONE REPLACEMENT THERAPY 2
 

Managing both nasal and ocular symptoms in patients

  • 1. Managing both nasal and ocular symptoms in patients with moderate to severe seasonal allergic rhinitis (SAR) “When we think about allergic rhinitis, we forget that the eyes come along.” http://kardzmed.com OBJECTIVE:
  • 2. that about 75% of the most severe SAR patients complain of itchy eyes and about two thirds of them complain of watery eyes there's been a lot of interest in looking at combinations of nasal antihistamines and nasal corticosteroids, with previous studies showing that the combination is more effective statistically than the single entities http://kardzmed.com Basis of Research
  • 3. Paul Ratner, MD, allergist/immunologist and founder and director of Sylvana Research, of San Antonio, Texas, a research facility for investigational medications. http://kardzmed.com Lead Reasearcher
  • 4. the ocular effects from treatment with this combination. http://kardzmed.com Aim of study“Treat the Eyes and the Nose”
  • 5. His investigational team enrolled 610 patients with ocular symptoms from SAR during the 2007/08 Texas Mountain Cedar season. The patients were randomized to 1 of 4 groups receiving 1 spray per nostril twice daily: azelastine alone, fluticasone alone, azelastine plus fluticasone, and placebo. http://kardzmed.com Procedure
  • 6. The primary end point was efficacy, defined as a change from baseline in the total nasal symptom score (TNSS) for nasal congestion, sneezing, itchy nose, and runny nose. The secondary end point was the effect of azelastine plus fluticasone on the total ocular symptom score (TOSS) for itchy eyes, watery eyes, and redness http://kardzmed.com Set objectives to investigate
  • 7. Results were presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2009 Annual Scientific Meeting in a podium session http://kardzmed.com Results
  • 8. Nasal and Ocular Symptoms Improved improvements on TNSS were statistically significant for the patients treated with the combination spray compared with single drug http://kardzmed.com 1. TNSS
  • 9. There was also a statistically significant improvement in TOSS for those treated with the combination spray http://kardzmed.com 2. TOSS
  • 10. The only adverse events reported by more than 2% of those treated with the combination spray were bitter taste (7.2%), epistaxis(3.9%), and headache (2.6%). http://kardzmed.com adverse effects
  • 11. The first is that the combination therapy with nasal antihistamines and nasal steroids is definitely panning out to be more effective than treatment with the individual components Second, in addition to treating the nasal symptoms that you would expect, you're also getting the added benefit of having relief of the ocular symptoms." http://kardzmed.com Conclusion
  • 12. allergists are now using both drugs in combination in 30% to 40% of their patients. So what this study reinforces is that polypharmacy, using an antihistamine blocker as well as a nasal steroid, may be a more effective modality in treating this ocular complaint and the nasal symptoms http://kardzmed.com
  • 13. This study was funded by Meda pharmaceuticals November 13, 2009 (San Diego, California) Presented in ENT class (Ml410) by Dr. Karl http://kardzmed.com http://kardzmed.com THE END